Company intelligence / Profile preview
Astrion
Seoul/Gyeonggi-do*, South Koreaastrion.co.kr ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Astrion has developed a proprietary drug screening platform to identify modulators targeting key factors in brain diseases. The company focuses on dual-targeted protein degradation mechanisms involving ANO1 and EGFR, with applications in both cancer diagnostics/therapeutics and neurodegeneration. They have also developed gold nanoparticle-based companion diagnostic kits but have not reported late-stage clinical results yet.
- Therapeutic areas
- OncologyNeurology
- Modalities
- Protein degraderSmall moleculeNanoparticle
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Astrion.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Astrion.